Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2020.0293


Genomic and transcriptomic landscapes in the management of breast cancer.

Prof. George Zografos, MD, PhD.


The breakthrough combination of two targeted drugs, specifically the addition of pertuzumab or neratinib to trastuzumab and chemotherapy has led to impressive oncological outcome benefits in both adjuvant/neo-adjuvant and metastatic HER2 positive breast cancer1-3. However, longer follow-up results are required to access potential higher late recurrence rates. Emerging rational research in genome and transcriptome exploration could reduce late recurrence rates for HER2 positive as well as to improve oncological outcomes of HER2 negative and triple negative breast cancer.

(Citation: Gastric & Breast Cancer 2020; 15(1): 25-30)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 15 January 2020